These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3347093)

  • 1. Low dose Ara-C for patients with myelodysplastic syndromes.
    Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
    Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of low-dose Ara-C in the treatment of refractory, atypical leukemia and myelodysplastic syndrome].
    Tsubaki K; Horiuchi A; Nagai K; Kanamaru A; Kohsaki M; Kitani T; Tagawa S; Masaoka T; Shibata H; Yasunaga K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):996-1003. PubMed ID: 3457553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).
    Jehn U; Göldel N; Vehling-Kaiser U
    Anticancer Res; 1987; 7(3 Pt B):505-8. PubMed ID: 3477124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
    Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
    J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.
    Zwierzina H; Suciu S; Loeffler-Ragg J; Neuwirtova R; Fenaux P; Beksac M; Harousseau J; Nuessler V; Cermak J; Solbu G; Willemze R; de Witte T; Amadori S;
    Leukemia; 2005 Nov; 19(11):1929-33. PubMed ID: 16151466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes.
    Aul C; Schneider W
    Cancer; 1989 Nov; 64(9):1812-8. PubMed ID: 2790694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
    Katayama N; Tanaka I; Minami N; Shirakawa S
    Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.
    Powell BL; Capizzi RL; Muss HB; Bearden JD; Lyerly ES; Rosenbaum DL; Morgan TM; Richards F; Jackson DV; White DR
    Leukemia; 1989 Jan; 3(1):23-8. PubMed ID: 2642574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
    Creutzig U; Cantù-Rajnoldi A; Ritter J; Romitti L; Odenwald E; Conter V; Riehm H; Masera G
    Am J Pediatr Hematol Oncol; 1987; 9(4):324-30. PubMed ID: 3439582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
    Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
    Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
    Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
    Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
    Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective study of 30 cases of myelodysplastic syndrome according to the French-American-British classification].
    Piguet D; Schmidt PM; Delacrétaz F; Mermillod B
    Schweiz Med Wochenschr; 1987 Jan; 117(2):61-6. PubMed ID: 3468610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
    Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
    Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.